FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.

摘要: Abstract Background Although the survival benefit of cisplatin-based adjuvant chemotherapy has been proven for patients with non small cell lung cancer (NSCLC), resistance to cisplatin and its dose-dependent side effects remain a challenge. Improvement in reduction require biomarker capable defining response treatments NSCLC. FATS is newly identified tumor suppressor involved DNA damage-induced carcinogenesis. In this study, we investigated whether quantified mRNA expression can predict sensitivity Methods The level samples from receiving an initial diagnosis NSCLC ( n =89) was determined by quantitative real-time reverse transcription PCR. histological characteristics were retrospectively reviewed. Cisplatin-induced apoptosis cells evaluated flow cytometry after Annexin V staining. Results significantly downregulated compared normal tissues same patient P =0.001). Low correlated poor overall =0.030). For those chemotherapy, longer FATS-high subgroup than that FATS-low =0.038). Multivariate analysis revealed independent value predicting chemotherapy. Furthermore, enhanced sensitized cisplatin-induced apoptosis. Conclusion relatively high provides new good outcome